Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: A Two-Case Series
DOI:
https://doi.org/10.5281/zenodo.22649004Keywords:
Checkpoint Inhibitor Myocarditis Managed With Early Abatacept, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
Checkpoint Inhibitor Myocarditis Managed With Early Abatacept is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for checkpoint
inhibitor myocarditis managed with early abatacept, spanning analytical, clinical, implementation, governance, and economic
dimensions, focusing on where practice has converged and where it continues to vary, and set out the practical considerations
relevant to a service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence
currently available, rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.2196/48297
Brankovic K, Kowalczyk B, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.1007/s00330-025-12031-z
Castellani R, Ristic C, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.3389/fdgth.2026.1699005
Dumitrescu A, Andric D, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1834800
Eriksdottir B, Brankovic E, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.2196/69678
Farkas I, Ionescu F, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.7759/cureus.46454
Grabowski P, Petrescu G, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.1016/j.ssci.2025.107028
Hendriksen W, Wojcik H, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.2196/48633
Ionescu F, Foscarini I, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1371/journal.pone.0305949
Jankowiak G, Grabowski J, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1371/journal.pdig.0000514
Kowalczyk N, Novotna K, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.17219/acem/208596
Lindqvist U, Urbanek L, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a methodological appraisal". PLoS7 Med 30(2014): 201-209. DOI: 10.7759/cureus.104086
Marchetti D, Doncheva M, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1038/s41746-023-00852-5
Novotna E, Eriksdottir N, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1016/j.mayocpiqo.2022.09.004
Ostrowski L, Lindqvist O, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1177/08404704241291226
Petrescu S, Szabo P, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1093/medlaw/fwad013
Quintero B, Balogh Q, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.2196/89834
Ristic C, Castellani R, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.1007/s10916-024-02104-9
Szabo J, Jankowiak S, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.3389/fdgth.2026.1896184
Tarasov Q, Quintero T, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3390/diagnostics15162117
Urbanek Z, Zielinski U, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.4103/jrpp.jrpp_20_65
Vasquez A, Alvez V, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.3389/fdgth.2026.1763884
Wojcik H, Hendriksen W, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.2196/48297
Zielinski O, Ostrowski Z, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.1007/s00330-025-12031-z
Andric V, Vasquez A, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.3389/fdgth.2026.1699005
Balogh E, Emmerich B, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1834800
Chiriac F, Farkas C, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.2196/69678
Doncheva M, Marchetti D, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a validation study". Trials 22(2017): 377-383. DOI: 10.7759/cureus.46454
Emmerich T, Tarasov E, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.1016/j.ssci.2025.107028
Foscarini C, Chiriac F, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.2196/48633
Alvez D, Dumitrescu A, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1371/journal.pone.0305949
Brankovic K, Kowalczyk B, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1371/journal.pdig.0000514
Castellani R, Ristic C, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.17219/acem/208596
Dumitrescu A, Andric D, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.7759/cureus.104086
Eriksdottir B, Brankovic E, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1038/s41746-023-00852-5
Farkas I, Ionescu F, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1016/j.mayocpiqo.2022.09.004
Grabowski P, Petrescu G, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1177/08404704241291226
Hendriksen W, Wojcik H, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1093/medlaw/fwad013
Ionescu F, Foscarini I, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a scoping review". JAMA 44(2020): 498-506. DOI: 10.2196/89834
Jankowiak G, Grabowski J, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.1007/s10916-024-02104-9
Kowalczyk N, Novotna K, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.3389/fdgth.2026.1896184
Lindqvist U, Urbanek L, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3390/diagnostics15162117
Marchetti D, Doncheva M, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.4103/jrpp.jrpp_20_65
Novotna E, Eriksdottir N, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.3389/fdgth.2026.1763884
Ostrowski L, Lindqvist O, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.2196/48297
Petrescu S, Szabo P, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.1007/s00330-025-12031-z
Quintero B, Balogh Q, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.3389/fdgth.2026.1699005
Ristic C, Castellani R, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1834800
Szabo J, Jankowiak S, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.2196/69678
Tarasov Q, Quintero T, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.7759/cureus.46454
Urbanek Z, Zielinski U, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.1016/j.ssci.2025.107028
Vasquez A, Alvez V, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.2196/48633
Wojcik H, Hendriksen W, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1371/journal.pone.0305949
Zielinski O, Ostrowski Z, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1371/journal.pdig.0000514
Andric V, Vasquez A, et al. "Checkpoint Inhibitor Myocarditis Managed With Early Abatacept: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.17219/acem/208596
